Quest Diagnostics Incorporated, BGI Group, and Dassault Systèmes Dominated the Asia-Pacific Bioinformatics Market in 2020

Asia-Pacific Bioinformatics Market is expected to grow at a CAGR of 14.1% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @

Asia-Pacific bioinformatics is a highly fragmented market, which includes number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.

Major players operating in the market are introducing a wide range of products. This helps them maximize their sales with enhanced product portfolio.

For instance,

  • In December 2020, Eurofins Scientific’s genomics launched a SARS-CoV-2 next-generation sequencing service that provides entire viral genome sequences at a low cost. The synthesis division had also created a best-in-class ARTIC NGS Oligo mix, which will be commercial across worldwide. For multiplexed PCR amplification of the whole viral genome, the ARTIC method will be used as an oligo pool and the company can optimize the oligo pool formulation to achieve best-in-class performance and uniformity of coverage for full-length viral genome, which further helped the company make a footprint in the bioinformatics market by developing such innovative technologies

Quest Diagnostics Incorporated is the dominating player in Asia-Pacific bioinformatics market. Other key players existing in the market are Thermo Fisher Scientific Inc., Agilent Technologies, Inc., QIAGEN, BGI, PerkinElmer Inc., Innoplexus, Eurofins Scientific, WATERS, SOPHiA GENETICS, Partek, Incorporated, DNASTAR, DASSAULT SYSTEMES, DNANEXUS, INC., Syntekabio,, Inc., Quest Diagnostics Incorporated, Accely Group, and others.

Asia-Pacific Bioinformatics MarkeQuest Diagnostics Incorporated

Quest Diagnostics Incorporated was established in the year 1999 and its headquarter is located in the U.S. The Company is focused on producing advanced diagnostic services and information across the world. DIS Business and DS Business are the major business segments of the company. In addition, the company has a wide range of product categories including patients, physicians & hospitals, companies & organization, in which physicians &hospitals is a market focused category.

  • In May 2021, Quest Diagnostics Incorporated announced its collaboration with Paige, which builds computational pathology products. With this collaboration, the company will develop new software products that will help pathologists, oncologists, and others diagnose diseases efficiently. With this, the company will leave a footprint in the diagnostic space.

The company offers services in all over North America, Europe, Asia-Pacific, and the Middle East and Africa regions.

Dassault Systèmes

The company was established in 1981 and it’s headquarter is located in France.  It offers solutions on life science, healthcare, manufacturing industries, and other infrastructure facilities across the world. The major business segments of the company are transportation & mobility, aerospace & defense, marine & offshore, industrial equipment, high-tech, home & lifestyle, consumer packaged goods & retail, life sciences, energy & materials, construction, cities & territories, construction, and cities & territories, from which life sciences is a market focused segment. In addition, the company offers a wide range of product categories including CATIA, SOLIDWORKS, ENOVIA, DELMIA, SIMULIA, GEOVIA, 3DVIA, BIOVIA, NETVIBES, 3DEXCITE, and Centric PLM, MEDIDATA under which BIOVIA is a market focused category.

  • In June, Medidata, a Dassault Systèmes company, announced the launch of Medidata Decentralized Clinical Trials (DCT) Program, which secures technologies that enable full decentralization across the clinical trial continuum. This platform will help minimize the opportunity for data discrepancies and transfer lags, which may lead to security concerns and increased risk of trial disruption. This will help the company expand its portfolio.
  • In July, Medidata, a Dassault Systèmes company, announced that it is collaborating with Moderna, Inc. to support clinical trials of mRNA-1273. The company will be using Medidata Rave technologies to help support and accelerate clinical development. With this, the company will be able to penetrate deep into the market.

The company has presence across the globe in North America, Europe, Asia-Pacific, and Africa.


The company was founded in 2013 with its headquarter based in New Zealand. The company is engaged in developing bioinformatics solutions and interpretations for sequencing of data. Geneious Prime and Geneious Biologics are the product categories offered by the company, both of which are market focused.

  • In June 2019, Geneious collaborated with Abveris, which is an antibody discovery services company. With this collaboration, the company has started using Geneious Biologics data analysis platform to develop new Single Clone Antibody Annotator pipelinefor. Through this, Geneious had enhanced and optimized the operation concerning the antibody NGS data.